Ex Parte DENEFLE et al - Page 4




              Appeal No. 2004-0456                                                                                     
              Application No. 08/913,699                                                                               
                           Therefore, it would have been prima facie obvious to one of                                 
                    ordinary skill in the art at the time the invention was made to have inserted                      
                    cDNA of Baer et al. or the genomic DNA of McLean et al. encoding the                               
                    human LCAT into the replication defective adenovirus of Benoit et al.,                             
                    either in place of, or in addition to the nucleic acid sequence encoding                           
                    apoA-1 and administered it to an individual wit the effect of stimulating                          
                    cholesterol efflux.  One [would] have had a reasonable expectation of                              
                    success in making the virus since all components required were known                               
                    and Benoit et al. taught how to make them, and success in administering                            
                    the virus to patients and expressing the LCAT and apoA-1, if present, in                           
                    liver cells, since Benoit et al. taught that the virus could be administered in                    
                    vivo and the transgene expressed in liver cells.   One would also [have]                           
                    had a reasonable expectation of success that at least some cholesterol                             
                    efflux would occur since Benoit et al. taught that expression of human                             
                    apoA-1 would also have that effect.  One would have done so because                                
                    Benoit et al. taught that gene therapy held much promise for treating                              
                    dyslipoproteinemias by supplying the gene encoding a protein that was                              
                    deficient, e.g. apoA-1, and Baer et al. taught that LCAT protein, alone or                         
                    with apoA-1 protein could be administered to treat dyslipoproteinemias                             
                    due to LCAT deficiency, with the result of mobilizing cellular and                                 
                    atherosclerotic plaque cholesterol to HDL and hence out of the cells and                           
                    bloodstream.   These teachings would clearly motivate one of ordinary                              
                    skill in the art to make the recited viral vector comprising the gene                              
                    encoding human LCAT and administer it to individuals for delivery and                              
                    expression of the transgene(s) in vivo for clinical research.                                      

                    Appellants respond, arguing the examiner has failed to set forth a prima facie                     
              case of obviousness (Brief, page 6) as there is no clear and particular evidence of                      
              record to support the Office's conclusion that one of ordinary skill in the art would have               
              been motivated to combine the teachings of Benoit, Baer, and McLean to arrive at the                     
              claimed invention.                                                                                       





                                                          4                                                            





Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007